Oppenheimer Discouraged on Teva’s Ability to Generate Gains in the Short-Term

Is Teva Pharmaceutical (NYSE:TEVA) overpriced? For a company that just released a third quarter print, Oppenheimer analyst Derek Archila does not have any sense of improved conviction on the beleaguered biotech giant’s growth arc.

Story Continues